Home/Pipeline/ONO-2910

ONO-2910

Neuropathic Pain

Phase 2Active

Key Facts

Indication

Neuropathic Pain

Phase

Phase 2

Status

Active

Company

Ono Pharmaceutical

About Ono Pharmaceutical

Ono Pharmaceutical's mission is to address unmet medical needs through the discovery and development of first-in-class and best-in-class therapeutic agents. The company has achieved global recognition primarily through its strategic alliance with Bristol Myers Squibb on the blockbuster PD-1 inhibitor Opdivo (nivolumab), which established its strong foothold in immuno-oncology. Its strategy centers on sustained internal R&D investment, complemented by strategic partnerships and in-licensing to expand its pipeline and global commercial reach. Ono is now executing a multi-faceted growth plan to diversify its portfolio beyond Opdivo and solidify its position as a global specialty pharma leader.

View full company profile

Therapeutic Areas

Oncology Immunology Neurology

Other Neuropathic Pain Drugs

Drug	Company	Phase	Status
NTRX-07	NeuroTherapia	Pre-clinical	Active
Neuropathic Pain Model Service	NeuroProof	Pre-clinical	Active
Sana Device for Neuropathic Pain	Sana Health	Pivotal Trial Completed	Active
Neuropathic Pain Program	VersaPeutics	Preclinical	Active
Cerebro Platform for Pain	Vonova.io	Pre-clinical	Active
ZYNPN	Zyneyro	Pre-clinical	Active
XT-150 (Preclinical)	Xalud Therapeutics	Preclinical	Active
VX-548	Vertex Pharmaceuticals	Phase 2	Active
BDT272	KYORIN Pharmaceutical	Preclinical	Active (In-licensed)
HSK16149	Haisco Pharmaceutical Group	Phase III	Active
GRC-301	Grace Therapeutics	Preclinical	Candidate optimization